Literature DB >> 16865574

Neuropsychiatric complications after liver transplantation: role of immunosuppression and hepatitis C.

Claudio R Tombazzi1, Bradford Waters, M Hosein Shokouh-Amiri, Santiago R Vera, Caroline A Riely.   

Abstract

Neuropsychiatric complications are an important source of morbidity following orthotopic liver transplantation. Etiology of liver disease and type of immunosuppression are possible related factors. The aim of this study was to describe the prevalence of neuropsychiatric complications after liver transplantation, the role of immunosuppression, and the association between these and specific liver diseases such as hepatitis C. One hundred twenty-eight patients with liver transplants were studied. Tacrolimus was the primary immunosuppressant in 101 patients and cyclosporine in 27 patients. Seventy-five complications in 49 patients (38.2%) were reported. In 43 patients, the etiology was associated with immunosuppression: 36 on tacrolimus and 7 on cyclosporine (P = 0.34). Seventeen and four-tenths percent of patients with hepatitis C and 4.6% of patients without hepatitis C developed depression (P = 0.02). There is no difference between types of primary immunosuppression and neuropsychiatric complications. There is a significantly greater incidence of depression in patients transplanted for hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865574     DOI: 10.1007/s10620-006-8012-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

Review 1.  Hepatitis C, interferon alfa, and depression.

Authors:  D Zdilar; K Franco-Bronson; N Buchler; J A Locala; Z M Younossi
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

2.  [Late cryptococcal meningitis after liver transplantation].

Authors:  J Dumortier; M A Piens; O Boillot; J L Faure; J Y Scoazec; F Berger; P Paliard
Journal:  Gastroenterol Clin Biol       Date:  1999-11

3.  Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506.

Authors:  O L Lopez; A J Martinez; J Torre-Cisneros
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Cerebral aspergillosis in liver transplantation.

Authors:  A P Boon; D H Adams; J Buckels; P McMaster
Journal:  J Clin Pathol       Date:  1990-02       Impact factor: 3.411

5.  Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity.

Authors:  B A Appignani; R A Bhadelia; S C Blacklow; A K Wang; S F Roland; R B Freeman
Journal:  AJR Am J Roentgenol       Date:  1996-03       Impact factor: 3.959

Review 6.  Neurologic complications of liver transplantation.

Authors:  A J Martinez; C Estol; A A Faris
Journal:  Neurol Clin       Date:  1988-05       Impact factor: 3.806

7.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

8.  Coccidioidomycosis in liver transplant patients.

Authors:  C D Holt; D J Winston; B Kubak; D K Imagawa; P Martin; L Goldstein; K Olthoff; J M Millis; A Shaked; C R Shackleton; R W Busuttil
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

9.  Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol.

Authors:  P C de Groen; A J Aksamit; J Rakela; G S Forbes; R A Krom
Journal:  N Engl J Med       Date:  1987-10-01       Impact factor: 91.245

10.  Cerebral blindness and encephalopathy with cyclosporin A toxicity.

Authors:  A M Rubin; H Kang
Journal:  Neurology       Date:  1987-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.